Previous studies have demonstrated that proliferation, stroma or immunity strongly influence the prognosis and therapeutic resistance of diffuse large B-cell lymphoma (DLBCL). Herein, we aimed to integrate proliferation, stromal, and immune (PSI) feature
She highlighted early from the phase 1/2 GO40554 study (NCT03677154) to treat patients with diffuse large B-cell lymphoma in the frontline setting. Initial data show a CR rate of 42% References Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of ...
The first study involved 879 individuals with newly diagnosed diffuse large B cell lymphoma, the most common type of lymphoma. For the past 20 years, these patients have been receiving a regimen known as R-CHOP—but only about two-thirds are typically cured. Many clinical trials over the year...
Notably, the International Lymphoma Case-Control consortium (InterLymph) reported inflammatory responses as important for diffuse large B-cell lymphoma (DLBCL) etiology by demonstrating associations between interleukin 10 (IL10) and tumor necrosis factor-a polymorphisms in NHL and DLBCL risk .Wang S...
et al. Recruitment of natural killer cells in advanced stages of endogenously arising B-cell lymphoma: implications for therapeutic cell transfer. J. Immunother. 35, 217–222 (2012). Article CAS PubMed Google Scholar Haabeth, O. A. W. et al. Inflammation driven by tumour-specific Th1 ...
cochlear implant, congenital or acquired asplenia, CSF leak, diabetes mellitus, generalized malignancy, HIV, Hodgkin disease, immunodeficiency, iatrogenic immunosuppression, leukemia, lymphoma, multiple myeloma, nephrotic syndrome, solid organ transplants, or sickle cell disease or other hemoglobinopathies. ...
Exosomes have emerged as a novel mode of intercellular communication. Exosomes can shuttle bioactive molecules including proteins, DNA, mRNA, as well as non-coding RNAs from one cell to another, leading to the exchange of genetic information and reprogra
"The potential of this discovery is huge. It helps us to understand how we may be able to treat diseases that affect theimmune systemitself, such as HIV or B cell lymphoma," Dr Kallies said. Professor Sharon Lewin, the Director of the Peter Doherty Institute for Infection and Immunity, a...
On the new drug approval front. The FDA has asked Roche to provide longer-term data for its Polivy application in first-line diffuse large B-cell lymphoma and for T-cell engager Lunsumio (mosunetuzumab) in follicular lymphoma. In both cases, European regulators have cleared ...
E. et al. Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity. J. Med. Chem. 54, 1914–1926 (2011). CAS PubMed Google Scholar Tanaka, Y. et al. Discovery of potent Mcl-1/Bcl-xL ...